TNF and Alzheimer disease: In other words, a phase II, double-blind, randomized study showed that weekly subcutaneous injections of TNFα(Etanercept) in a tiny number of mild to moderate AD dementia patients had no significant results as compared with placebo (Holbrook et al., 2021).